Max N. Wallace
Chief Executive Officer, Accelerate Brain Cancer Cure
Mr. Max Wallace previously served as President and Chief Executive Officer of Cogent Neuroscience, a biopharmaceutical company that used novel live-tissue technology to discover drugs for the treatment of neurological diseases. Prior to his tenure as founder and CEO of Cogent in 1998, Wallace served on the Board of Directors of Trimeris, Inc., a public anti-viral research company based in Durham, NC that he also helped establish. In addition to Cogent and Trimeris, Wallace also founded Sphinx Pharmaceuticals Corporation, a public cellular signal transduction company now part of Eli Lilly & Co., and SARCO, Inc., a combinatorial chemistry company now part of PPD/Pharmaco. In addition to his entrepreneurial experience, Wallace has held various positions with Duke University, most recently as one of the founding directors of Duke Management Company, the University’s asset management company. Here he developed novel approaches to technology development and new business creation for the university. Before coming to Duke in 1983, Mr. Wallace spent a number of years in private legal practice representing commercial and technology clients. Wallace received his B.A from Duke University and his law degree from the University of Florida College of Law.